Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Overview | 8 | 1 |
| Therapeutics Development | 9 | 4 |
| Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Products under Development by Stage of Development | 9 | 1 |
| Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Products under Development by Therapy Area | 10 | 1 |
| Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Products under Development by Indication | 11 | 2 |
| Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Pipeline Products Glance | 13 | 2 |
| Late Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Products under Development by Companies | 15 | 6 |
| Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Therapeutics Assessment | 21 | 6 |
| Assessment by Monotherapy/Combination Products | 21 | 1 |
| Assessment by Mechanism of Action | 22 | 1 |
| Assessment by Route of Administration | 23 | 2 |
| Assessment by Molecule Type | 25 | 2 |
| Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Companies Involved in Therapeutics Development | 27 | 9 |
| Array BioPharma Inc. | 27 | 1 |
| AstraZeneca Plc | 28 | 1 |
| Eisai Co., Ltd. | 29 | 1 |
| F. Hoffmann-La Roche Ltd. | 30 | 1 |
| GlaxoSmithKline Plc | 31 | 1 |
| Merck &Co., Inc. | 32 | 1 |
| Merck KGaA | 33 | 1 |
| Novartis AG | 34 | 2 |
| Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Drug Profiles | 36 | 47 |
| binimetinib Drug Profile | 36 | 7 |
| binimetinib + encorafenib Drug Profile | 43 | 2 |
| CIP-137401 Drug Profile | 45 | 1 |
| cobimetinib fumarate Drug Profile | 46 | 6 |
| dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide Drug Profile | 52 | 1 |
| dabrafenib mesylate + panitumumab + trametinib dimethyl sulfoxide Drug Profile | 53 | 1 |
| dabrafenib mesylate + trametinib dimethyl sulfoxide Drug Profile | 54 | 7 |
| E-6201 Drug Profile | 61 | 2 |
| EBI-1051 Drug Profile | 63 | 1 |
| MK-2206 + selumetinib sulfate Drug Profile | 64 | 1 |
| pimasertib hydrochloride Drug Profile | 65 | 3 |
| pimasertib hydrochloride + voxtalisib Drug Profile | 68 | 2 |
| RG-7304 Drug Profile | 70 | 1 |
| selumetinib sulfate Drug Profile | 71 | 5 |
| trametinib dimethyl sulfoxide Drug Profile | 76 | 5 |
| trametinib dimethyl sulfoxide + uprosertib Drug Profile | 81 | 2 |
| Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Dormant Projects | 83 | 8 |
| Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Discontinued Products | 91 | 2 |
| Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2) Featured News &Press Releases | 93 | 16 |
| Jun 30, 2016: Array BioPharma Submits Binimetinib New Drug Application to U.S. FDA | 93 | 1 |
| Jun 06, 2016: Array Presents Full Results from Phase 3 NEMO Study | 94 | 1 |
| Jun 06, 2016: Novartis combination therapy Tafinlar + Mekinist demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma | 95 | 1 |
| Jun 06, 2016: Novartis pivotal data for Tafinlar + Mekinist demonstrated a 63 percent overall response rate in treating rare form of lung cancer | 96 | 1 |
| Jun 05, 2016: Exelixis Announces Genentech Presentation of Preliminary Phase 1B Trial Results for the Combination of Cobimetinib and Atezolizumab at ASCO 2016 Annual Meeting | 97 | 1 |
| Jun 03, 2016: Cobimetinib in advanced melanoma with BRAF V600 mutation: Added benefit now considerable | 98 | 1 |
| May 18, 2016: Array BioPharma Announces Key Data from NRAS-mutant Melanoma at ASCO 2016 | 99 | 1 |
| May 12, 2016: Selumetinib granted Orphan Drug Designation in the US for adjuvant treatment of differentiated thyroid cancer | 100 | 1 |
| Apr 29, 2016: NICE recommends combined drug therapy proven to extend life for skin cancer | 101 | 1 |
| Apr 20, 2016: Exelixis Announces Presentation On Cobimetinib At 2016 ASCO Annual Meeting | 101 | 2 |
| Apr 01, 2016: Array BioPharma Announces Decision To Discontinue MILO Study In Ovarian Cancer | 103 | 1 |
| Mar 22, 2016: Many Targeted Cancer Therapies Suppress T Cell Immune Responses | 103 | 1 |
| Feb 25, 2016: New targeted therapy for treatment of serious form of skin cancer approved in Canada | 104 | 2 |
| Jan 13, 2016: Dabrafenib/trametinib in advanced BRAF V600 mutated melanoma: Indication of added benefit | 106 | 1 |
| Dec 16, 2015: Array BioPharma Announces Phase 3 Binimetinib Trial Meets Primary Endpoint For NRAS-Mutant Melanoma | 107 | 2 |
| Appendix | 109 | 2 |
| Methodology | 109 | 1 |
| Coverage | 109 | 1 |
| Secondary Research | 109 | 1 |
| Primary Research | 109 | 1 |
| Expert Panel Validation | 109 | 1 |
| Contact Us | 109 | 1 |
| Disclaimer | 110 | 1 |